MRK vs NVO
Merck & Co. and Novo Nordisk A/S, both Healthcare
Merck & Co. is the larger company at $281B against $211B. Over the past year MRK returned +83% against -35% for NVO. The RyuScore puts NVO ahead, 88 against 78 out of 100.
| Figure | MRK | NVO |
|---|---|---|
| Last close | $146 | $38.62 |
| Market cap | $281B | $211B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 115.5 | n/a |
| Dividend yield | 2.3% | n/a |
| 1-year return | +83% | -35% |
| 5-year return | +132% | -15% |
| RyuScoresector-relative, 1–10 | 78/100 | 88/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Merck & Co.
Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.
Novo Nordisk A/S
Open these two in the interactive comparison to add more names, change the period or see the correlation.